Recall of Specific Types of Breast Implants and Tissue Expanders Has Far-Reaching Impact on Patients With Breast Cancer
In Japan, insurance coverage for breast implantation is limited to procedures using Allergen-manufactured products.
Lymphoma News
LYMPHOMA ADVISOR
Lymphoma News
Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Radiotherapy Response Time Did Not Dictate Outcomes for Gastrointestinal Low-Grade B-Cell Lymphoma
Delayed evaluation could decrease unnecessary invasive tests.
COVID-19, SARS-CoV-2 Infection Phenotypes Vary With Different Tumor Subtypes
Among patients with cancer, tumor subtypes may influence varying susceptibility to SARS-CoV-2 and COVID-19 disease phenotypes.
Waldenström Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow-Up
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
Low-Dose Anti–PD-1 Therapies in Relapsed/Refractory Classical Hodgkin Lymphoma
A small study suggests that low-dose pembrolizumab or nivolumab may be effective and safe for the treatment of r/r classical Hodgkin lymphoma.
2021 Update on Diagnosis, Risk Stratification, and Management of Cutaneous B-Cell Lymphomas
Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.
Managing Skin Flare Reactions in Patients Receiving Mogamulizumab for Cutaneous T-cell Lymphoma
Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.
Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans
Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.
Characterization of Neurotoxicity After CAR-T in LBCL
Neurotoxicity is a common AE associated with CAR-T administration, but there are limited data characterizing it among patients with LBCL who received axi-cel.
Trends Suggest More AYA Lymphoma Survivors Being Engaged in Survivorship Discussions, But Improvements Needed
In this study, researchers determined that the quantity and quality of discussions regarding survivorship and late effects of treatment between AYA lymphoma survivors and their oncologists is improving, but survivorship information is still lacking.
Expert Q&A: Understanding the Oncogenic Role of HIV in Burkitt Lymphoma
While the rate of certain HIV-linked non-Hodgkin lymphomas has declined since the introduction of ART, the incidence of Burkitt lymphoma has remained steady.
Survival Outcomes and HIV Status Among Patients With Plasmablastic Lymphoma
Researchers studied clinical characteristics linked to overall survival and lymphoma-specific survival in patients with plasmablastic lymphoma.
Improving Survival in Younger Patients With Waldenström Macroglobulinemia
Researchers evaluated data from younger patients with Waldenström macroglobulinemia to determine features that predict outcomes in this patient population.
G-CSF Appears Safe in CAR-T–Treated Patients With Refractory/Relapsed B-Cell Lymphoma
The treatment reduced hospital stay but not neutropenia duration or infection rate.
Development of a Tool to Predict Neurotoxicity Associated With CAR-T Therapy
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
Biomarker Identified for Anti–PD-1 Treatment in Natural Killer/T-Cell Lymphoma
All responders were found to have the same structural rearrangements.
Strategies for Managing AEs, Patient Adherence in Acalabrutinib for Mantle Cell Lymphoma
Researchers at UT MD Anderson Cancer Center in Houston present tools that support patient adherence to acalabrutinb in the setting of MCL.
Immunohistochemistry as a Surrogate for TP53 Sequencing in Mantle Cell Lymphoma
Identifying TP53 missense mutations through routine analysis is needed for patients with mantle cell lymphoma.
Risk-Stratified Treatments May Offer Cures in Relapsed Pediatric Anaplastic Large Cell Lymphoma
Study results suggest allogeneic SCT as standard consolidation therapy in pediatric patients with progression during frontline therapy or relapse of a CD3-positive ALCL.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
